Chemical inhibition of acetyl-CoA carboxylase suppresses self-renewal growth of cancer stem cells

Cancer stem cells (CSC) may take advantage of the Warburg effect-induced siphoning of metabolic intermediates into de novo fatty acid biosynthesis to increase self-renewal growth. We examined the anti-CSC effects of the antifungal polyketide soraphen A, a specific inhibitor of the first committed step of lipid biosynthesis catalyzed by acetyl-CoA carboxylase (ACACA). The mammosphere formation capability of MCF-7 cells was reduced following treatment with soraphen A in a dose-dependent manner. MCF-7 cells engineered to overexpress the oncogene HER2 (MCF-7/HER2 cells) were 5-fold more sensitive than MCF-7 parental cells to soraphen A-induced reductions in mammosphere-forming efficiency. Soraphen A treatment notably decreased aldehyde dehydrogenase (ALDH)-positive CSC-like cells and impeded the HER2's ability to increase the ALDH+-stem cell population. The following results confirmed that soraphen A-induced suppression of CSC populations occurred through ACACA-driven lipogenesis: a.) exogenous supplementation with supraphysiological concentrations of oleic acid fully rescued mammosphere formation in the presence of soraphen A and b.) mammosphere cultures of MCF-7 cells with stably silenced expression of the cytosolic isoform ACACA1, which specifically participates in de novo lipogenesis, were mostly refractory to soraphen A treatment. Our findings reveal for the first time that ACACA may constitute a previously unrecognized target for novel anti-breast CSC therapies.

[1]  M. V. Heiden,et al.  Targeting cancer metabolism: a therapeutic window opens , 2011, Nature Reviews Drug Discovery.

[2]  E. Maser,et al.  Targeting acetyl-CoA carboxylases: small molecular inhibitors and their therapeutic potential. , 2012, Recent patents on anti-cancer drug discovery.

[3]  A. Thor,et al.  Metformin Selectively Targets Tumor-Initiating Cells in ErbB2-Overexpressing Breast Cancer Models , 2013, Cancer Prevention Research.

[4]  M. Loda,et al.  New Strategies in Prostate Cancer: Targeting Lipogenic Pathways and the Energy Sensor AMPK , 2010, Clinical Cancer Research.

[5]  Y. Cui,et al.  Proteomics using mammospheres as a model system to identify proteins deregulated in breast cancer stem cells. , 2013, Current molecular medicine.

[6]  J. Ai,et al.  miR-143 inhibits glycolysis and depletes stemness of glioblastoma stem-like cells. , 2013, Cancer letters.

[7]  A. Allan,et al.  The Role of Human Aldehyde Dehydrogenase in Normal and Cancer Stem Cells , 2011, Stem Cell Reviews and Reports.

[8]  G. Daley,et al.  Stem cell metabolism in tissue development and aging , 2013, Development.

[9]  Alysha K Croker,et al.  Inhibition of aldehyde dehydrogenase (ALDH) activity reduces chemotherapy and radiation resistance of stem-like ALDHhiCD44+ human breast cancer cells , 2012, Breast Cancer Research and Treatment.

[10]  J. Brunet,et al.  Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb) in human breast carcinoma cells. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  J. Swinnen,et al.  ATP Citrate Lyase Knockdown Induces Growth Arrest and Apoptosis through Different Cell- and Environment-Dependent Mechanisms , 2012, Molecular Cancer Therapeutics.

[12]  A. Hinnen,et al.  Identification of the yeast ACC1 gene product (acetyl-CoA carboxylase) as the target of the polyketide fungicide soraphen A , 1994, Current Genetics.

[13]  Z. Darżynkiewicz,et al.  Potential anti-aging agents suppress the level of constitutive mTOR- and DNA damage- signaling , 2012, Aging.

[14]  M. Čuperlović-Culf,et al.  Targeting the latest hallmark of cancer: another attempt at 'magic bullet' drugs targeting cancers' metabolic phenotype. , 2012, Future oncology.

[15]  J. Menéndez,et al.  Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis , 2007, Nature Reviews Cancer.

[16]  Marta C Guadamillas,et al.  Overcoming anoikis – pathways to anchorage-independent growth in cancer , 2011, Journal of Cell Science.

[17]  Zhiwei Wang,et al.  Unraveling the mystery of cancer metabolism in the genesis of tumor-initiating cells and development of cancer. , 2013, Biochimica et biophysica acta.

[18]  H. Wu,et al.  Emodin-induced generation of reactive oxygen species inhibits RhoA activation to sensitize gastric carcinoma cells to anoikis. , 2008, Neoplasia.

[19]  B. Martín-Castillo,et al.  Metformin-induced preferential killing of breast cancer initiating CD44+CD24−/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts , 2012, Oncotarget.

[20]  V. Steele,et al.  Antidiabetic Drug Metformin Prevents Progression of Pancreatic Cancer by Targeting in Part Cancer Stem Cells and mTOR Signaling. , 2013, Translational oncology.

[21]  Sebastian Munck,et al.  De novo lipogenesis protects cancer cells from free radicals and chemotherapeutics by promoting membrane lipid saturation. , 2010, Cancer research.

[22]  A. Terzic,et al.  Lipid metabolism greases the stem cell engine. , 2013, Cell metabolism.

[23]  S. Volrath,et al.  Expression and characterization of recombinant fungal acetyl-CoA carboxylase and isolation of a soraphen-binding domain. , 2004, The Biochemical journal.

[24]  Z. Darżynkiewicz,et al.  Attenuation of constitutive DNA damage signaling by 1,25-dihydroxyvitamin D3 , 2012, Aging.

[25]  J. Menéndez,et al.  The mitochondrial H+-ATP synthase and the lipogenic switch , 2013, Cell cycle.

[26]  E. Cuyás,et al.  The Warburg effect version 2.0: Metabolic reprogramming of cancer stem cells , 2013, Cell cycle.

[27]  J. Debnath,et al.  PERK Integrates Autophagy and Oxidative Stress Responses To Promote Survival during Extracellular Matrix Detachment , 2011, Molecular and Cellular Biology.

[28]  Liang Tong,et al.  Acetyl‐coenzyme A carboxylases: Versatile targets for drug discovery , 2006, Journal of cellular biochemistry.

[29]  M. Tan,et al.  Stalling the engine of resistance: targeting cancer metabolism to overcome therapeutic resistance. , 2013, Cancer research.

[30]  Jim Watson,et al.  Oxidants, antioxidants and the current incurability of metastatic cancers , 2013, Open Biology.

[31]  Jung Weon Lee,et al.  Cholesterol depletion induces anoikis‐like apoptosis via FAK down‐regulation and caveolae internalization , 2009, The Journal of pathology.

[32]  M. Okada,et al.  Glioma‐Initiating Cell Elimination by Metformin Activation of FOXO3 via AMPK , 2012, Stem cells translational medicine.

[33]  M. Loda,et al.  Fatty acid synthase as a potential therapeutic target in cancer. , 2010, Future oncology.

[34]  Navdeep S. Chandel,et al.  AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress , 2012, Nature.

[35]  Liang Tong,et al.  A mechanism for the potent inhibition of eukaryotic acetyl-coenzyme A carboxylase by soraphen A, a macrocyclic polyketide natural product. , 2004, Molecular cell.

[36]  Martin Götte,et al.  Flow cytometry in cancer stem cell analysis and separation , 2012, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[37]  M. Tan,et al.  Targeting cellular metabolism to improve cancer therapeutics , 2013, Cell Death and Disease.

[38]  G. Wakabayashi,et al.  Resveratrol suppresses growth of cancer stem-like cells by inhibiting fatty acid synthase , 2011, Breast Cancer Research and Treatment.

[39]  B. Bao,et al.  Metformin Inhibits Cell Proliferation, Migration and Invasion by Attenuating CSC Function Mediated by Deregulating miRNAs in Pancreatic Cancer Cells , 2011, Cancer Prevention Research.

[40]  B. Martín-Castillo,et al.  Metformin: Multi-faceted protection against cancer , 2011, Oncotarget.

[41]  A. Gentles,et al.  Targeting Unique Metabolic Properties of Breast Tumor Initiating Cells , 2014, Stem cells.

[42]  T. Tsuruo,et al.  De novo fatty-acid synthesis and related pathways as molecular targets for cancer therapy , 2009, British Journal of Cancer.

[43]  F. Chiaradonna,et al.  Energy Metabolism Characterization of a Novel Cancer Stem Cell‐Like Line 3AB‐OS , 2014, Journal of cellular biochemistry.

[44]  E. López-Bonet,et al.  Metformin limits the tumourigenicity of iPS cells without affecting their pluripotency , 2012, Scientific Reports.

[45]  J. Swinnen,et al.  Chemical inhibition of acetyl-CoA carboxylase induces growth arrest and cytotoxicity selectively in cancer cells. , 2007, Cancer research.

[46]  M. Araúzo-Bravo,et al.  Metabolic control of adult neural stem cell activity by Fasn-dependent lipogenesis , 2012, Nature.

[47]  Matthew G. Vander Heiden,et al.  Metabolic targets for cancer therapy , 2013, Nature Reviews Drug Discovery.

[48]  Y. Mo,et al.  Elevated lipogenesis in epithelial stem-like cell confers survival advantage in ductal carcinoma in situ of breast cancer , 2013, Oncogene.

[49]  Daniel Birnbaum,et al.  ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. , 2007, Cell stem cell.

[50]  L. Partridge,et al.  Effects of resveratrol on lifespan in Drosophila melanogaster and Caenorhabditis elegans , 2007, Mechanisms of Ageing and Development.

[51]  L. Olson,et al.  Soraphen A, an inhibitor of acetyl CoA carboxylase activity, interferes with fatty acid elongation. , 2011, Biochemical pharmacology.

[52]  B. Martín-Castillo,et al.  The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells , 2011, Breast Cancer Research and Treatment.

[53]  Hanna Y. Irie,et al.  Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment , 2009, Nature.

[54]  M. Hidalgo,et al.  Metformin Targets the Metabolic Achilles Heel of Human Pancreatic Cancer Stem Cells , 2013, PloS one.

[55]  B. Wang,et al.  Synthesis and characterization of a BODIPY-labeled derivative of Soraphen A that binds to acetyl-CoA carboxylase. , 2009, Bioorganic & medicinal chemistry letters.

[56]  V. Sukhatme,et al.  ATP citrate lyase knockdown impacts cancer stem cells in vitro , 2013, Cell Death and Disease.

[57]  J. Menéndez Fine-tuning the lipogenic/lipolytic balance to optimize the metabolic requirements of cancer cell growth: molecular mechanisms and therapeutic perspectives. , 2010, Biochimica et biophysica acta.

[58]  K. Struhl,et al.  Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth , 2012, Proceedings of the National Academy of Sciences.

[59]  M. Wicha,et al.  HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion , 2008, Oncogene.

[60]  G. Sambuceti,et al.  Metformin selectively affects human glioblastoma tumor-initiating cell viability , 2013, Cell Cycle.

[61]  Yong‐Nyun Kim,et al.  Anoikis Resistance: An Essential Prerequisite for Tumor Metastasis , 2012, International journal of cell biology.